Risk factors for failing to complete gemcitabine–cisplatin neoadjuvant chemotherapy in muscle invasive bladder cancer patients
- Author:
Homin KANG
1
;
Jungyo SUH
;
Dalsan YOU
;
In Gab JEONG
;
Bumsik HONG
;
Jun Hyuk HONG
;
Hanjong AHN
;
Bumjin LIM
Author Information
- Publication Type:Original Article
- From: Investigative and Clinical Urology 2024;65(3):256-262
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:We evaluated the risk factors associated with failure to complete gemcitabine–cisplatin (GP) neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).
Materials and Methods:In total, 231 patients with MIBC treated with NAC before undergoing radical cystectomy between 2013 and 2022 participated in this study. Logistic regression analysis was performed to assess the relationship between the likelihood of incomplete NAC and clinical and demographic variables, including age, sex, hypertension (HTN), diabetes mellitus (DM), prechemotherapy glomerular filtration rate, clinical T stage, clinical N stage, and body mass index (BMI).
Results:Of 231 patients, 209 (90.5%) and 22 (9.5%) completed and discontinued the NAC course, respectively. The mean age was 66.13±9.15, 65.63±9.07, and 70.86±8.66 years for the total sample, continuation, and discontinuation groups, respectively (p=0.010). No significant inter-group differences in sex, HTN, height, weight, BMI, pre-chemotherapy glomerular filtration rate, clinical T stage, or clinical N stage were observed. According to the results of the multivariable analysis, age (odds ratio [OR] 1.076, 95% confidence interval [CI] 1.013–1.143, p=0.018) and the presence of DM (OR 2.541, 95% CI 1.028–6.281, p=0.043) were significantly associated with NAC discontinuation.
Conclusions:Thus, older age and presence of DM are potential risk factors for GP NAC discontinuation in patients with MIBC.Further studies are required to validate our findings and develop strategies to minimize the rate of GP NAC discontinuation in this population.
